NICE to assess Siemens' Clinitek Microalbumin 9 renal disease test strips
This article was originally published in Clinica
Executive Summary
The UK’s National Institute for Health and Clinical Excellence (NICE) is to evaluate Siemens’ Clinitek Microalbumin 9 urinalysis reagent strips for use in the early detection and monitoring of kidney disease. The product, which is marketed by Siemens Healthcare Diagnostics, based in Tarrytown, New York, will be assessed under the institute's medical technologies evaluation pathway (MTEP). All dates for the project have yet to be announced, but NICE is inviting stakeholders to register their interest in becoming involved in the assessment. The Clinitek urinalysis strips test for albumin, blood, creatinine, glucose, ketone, leukocyte, nitrite, pH and protein, and boasts automatic calculation of albumin-to-creatinine and protein-to-creatinine ratios.
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.